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Abstract
Hyaluronan (HA) is a linear polysaccharide with disaccharide repeats of D-glucuronic acid and N-
acetyl-D-glucosamine. It is evolutionary conserved and abundantly expressed in the extracellular
matrix (ECM), on the cell surface and even inside cells. Being a simple polysaccharide, HA
exhibits an astonishing array of biological functions. HA interacts with various proteins or
proteoglycans to organize the ECM and to maintain tissue homeostasis. The unique physical and
mechanical properties of HA contribute to the maintenance of tissue hydration, the mediation of
solute diffusion through the extracellular space and the lubrication of certain tissues. The diverse
biological functions of HA are manifested through its complex interactions with matrix
components and resident cells. Binding of HA with cell surface receptors activates various
signaling pathways that regulate cell function, tissue development, inflammation, wound healing
and tumor progression and metastasis. Taking advantage of the inherent biocompatibility and
biodegradability of HA, as well as its susceptibility to chemical modification, researchers have
developed various HA-based biomaterials and tissue constructs with promising and broad clinical
potential. In this article, we illustrate the properties of HA from a matrix biology perspective by
first introducing principles underlying the biosynthesis and biodegradation of HA, as well as the
interactions of HA with various proteins and proteoglycans. We next highlight the roles of HA in
physiological and pathological states, including morphogenesis, wound healing and tumor
metastasis. A deeper understanding of the mechanisms underlying the roles of HA in various
© 2013 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
*Corresponding author and reprint requests: Xinqiao Jia, Ph.D.: Phone: 302-831-6553; Fax: 302-831-4545; xjia@udel.edu Address:
201 DuPont Hall, Department of Materials Science and Engineering, University of Delaware, Newark, DE 19716.$Current address: University of Pittsburgh Medical Center, Department of Urology Research Laboratories, Shadyside Medical Center,
Suite G19, 5200 Centre Ave, Pittsburgh, PA 15232
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Acta Biomater. Author manuscript; available in PMC 2015 April 01.
Published in final edited form as:
Acta Biomater. 2014 April ; 10(4): 1558–1570. doi:10.1016/j.actbio.2013.12.019.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
physiological processes can provide new insights and tools for the engineering of complex tissues
and tissue models.
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1. Introduction
HA was purified first from the vitreous humor of bovine eyes by Karl Meyer in 1934 [1]. He
named the molecule “hyaluronic acid” owing to the hyaloid appearance of the substance
when swollen in water and the probable presence of hexuronic acid as one of the
components. In the 1950’s, Meyer and colleagues determined that HA was a linear
polysaccharide composed of repeating β-1,4-linked D-glucuronic acid (GlcA) and β-1,3-
linked N-acetyl-D-glucosamine (GlcNAc) disaccharide units (Figure 1A) [2]. The various
names of HA reflect the properties of the molecule under various conditions. When first
isolated, HA behaved like a mild acid; therefore, Meyer named it “hyaluronic acid” [1].
Under physiological conditions, HA exists as a polyelectrolyte with associated cations,
frequently as a sodium salt; therefore, the name sodium hyaluronate. The name was later
amended to “hyaluronate” in reference to its salt form or “hyaluronan,” a term used to
encompass all forms of the molecule [3].
HA is found ubiquitously in the ECM of all vertebrate tissues, although its concentration and
binding partners vary. In bodily fluids, the concentration of HA ranges from 0.01–0.1 µg/g
in blood serum to 1400–3600 µg/g in synovial fluid; HA content in soft connective tissues
ranges from 8.5–18 µg/g in the thoracic lymph to 140–338 µg/g in the vitreous body [4]. HA
also is present on some cell surfaces as a pericellular sugary coat, a feature thought to be
involved in cell differentiation and morphogenesis. In the cumulus cell-oocyte complex, the
HA concentration can be as high as 0.5–1.0 mg/mL [5, 6]. Classically considered an
extracellular molecule, the presence of HA in the cytoplasm and the nucleus was suggested
as early as the 1970’s [7, 8] and has been convincingly confirmed in the 1990’s [9–12].
Although intracellular HA has been suggested to play important roles in inflammation, its
intracellular functions remain largely unknown [13].
HA is not branched, nor does it contain any sulfate groups [14]. Despite its simple chemical
composition, HA fulfills several distinct molecular functions that contribute not only to the
structural and physiological characteristics of tissues but also to the mediation of cell
behaviors during morphogenesis, tissue remodeling, inflammation, and diseases. Owing to
its unique biophysical properties, HA contributes directly to the maintenance of tissue
homeostasis and biomechanics. Through its interactions with proteoglycans and link
proteins, HA organizes and maintains the structural integrity of extracellular and pericellular
matrices. As a signaling molecule, HA interacts with a variety of cell surface receptors and
HA-binding proteins to activate intracellular events to mediate cell functions [15].
After more than two decades of intense study, the molecular details of the role of HA in
normal and pathophysiological processes are finally emerging. The fascinating
characteristics of HA have motivated two distinct groups of scientists to investigate HA
related phenomena and applications. While biologists continue to unravel the complex
biological functions of HA and its receptors in various cell signaling processes, biomedical
engineers are creating a range of HA-based hydrogel materials with increasing complexity
and diverse functions for tissue regeneration purposes [16–18]. In this article, we highlight
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the essential biological functions of HA, with the goal of motivating the biomaterials
community to investigate HA both as a synthetic building block and a biological signaling
motif. This is not an all-inclusive review and the readers are referred to in-depth reviews in
an edited book for further reading [15].
2. Biosynthesis and degradation
Unlike other glycosaminoglycan (GAG) molecules that are synthesized in the Golgi
apparatus, HA is synthesized at the plasma membrane by a group of highly specialized
membrane proteins, HA synthases (HAS) [19]. There are three well-conserved HAS
isozymes present in mammalian species, HAS1, HAS2, and HAS3 [20], each possessing
two distinct binding domains for UDP-sugars (Figure 1B). Polymerization of HA occurs at
the inner face of the plasma membrane where HAS alternatively adds UDP-GlcA and UDP-
GlcNAc monomers to the reducing end of the growing polymer. As the polymerization is
occurring, the non-reducing end of the sugar chain is translocated into the extracellular
space through a pore in the HAS structure [21]. An intriguing question is why nature uses
three different isozymes for the synthesis of HA with such a simple repeating unit. Although
these three enzymes share a structural identity of about 55–70%, they differ in terms of their
ability to synthesize HA. HAS1 has a significantly higher Michaelis constant (Km) value,
the substrate concentration where the reaction rate is half of its maximum, for both UDP-
GlcA and UDP-GlcNAc compared to HAS2 and HAS3, suggesting that HAS1 has a slower
rate of HA synthesis compared to the other synthases [22, 23]. As discussed below, HA of
different sizes exhibits distinctly different, sometimes conflicting biological functions.
Therefore, the expression of various HAS isozymes is likely to be a fine control system
critical for the effective mediation of diverse cell behaviors. While HAS1 and HAS2 are
able to produce large-sized HA (up to 2,000 kDa), HA produced by HAS3 is of a lower
molecular mass (100–1,000 kDa) [22, 24]. McDonald and coworkers was the first to
recognize the isoform specificity for HA production in embryogenesis; they discovered that
HAS2 (but not HAS1 or HAS3) knock-out mice died at day 9.5 from incomplete
atrioventricular septum formation [25].
The expression levels of HAS isozymes differ during morphogenesis and in disease states
[26]. Thus, the differential distribution of HA in tissues varies at individual developmental
stages and in pathological conditions, and is controlled by the spatio-temporally regulated
transcription of the three different synthases. HA is abundant in fetal tissues, but is partially
replaced by collagen fibers and proteoglycans during development, so that the mature tissues
can fulfill more stringent mechanical tasks [27]. For example, the newborn vocal fold is
composed of a loose connective tissue rich in HA. As the vocal fold develops and matures,
HA content is reduced and the fibrous proteins are deposited across the lamina propria in a
gradient fashion. Overall, HA is indispensable for the vocal fold development and
maturation [28] and its presence in vocal fold is evolutionary beneficial for the tissue to cope
with constant trauma [29]. As discussed below, HA is enriched in tumors and tumor-
associated stromal tissues, possibly as a result of increased expression or activity of HAS
isozymes.
The diverse functions of HA originate from its primary and secondary structures [30, 31].
Connected by glycosidic links, individual saccharide units in HA are relatively rigid,
adopting a 4C1 chair with the bulky substituents located in sterically favorable equatorial
positions. X-Ray diffraction [32] and NMR [33] characterizations suggest that HA can adopt
stiff helical structures in solid state, possibly as a result of the chemical structure of the
disaccharide, extensive hydrophobic patch and internal hydrogen bonds. The presence of
multiple dynamically formed and broken hydrogen bonds between adjacent saccharides is
thought to contribute to the semiflexibility of the polymer chain in solution [33–35]. Using
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tapping mode AFM, Cowman and coworkers observed extended, relaxed and condensed
conformations of HA (Figure 2) that had been deposited on mica surfaces under various
conditions [36]. The researchers suggested that in connective tissue ECM, HA may adopt a
relaxed coil or partially condensed conformation, whereas HA tethered to the cell surface or
in cytosol may exist as fully condensed rods. When subjected to shear flow in tight
intercellular spaces or in protein-HA complexes, tissue HA may become fibrous.
At physiological pH, HA is a highly charged molecule containing associated counter ions,
such as Na+, K+, Ca2+ and Mg2+. Solutions of high molecular mass HA are highly viscous
because of polymer chain entanglement [37]. Such entangled networks display time-
dependent viscoelasticity, exhibiting elastic properties when subjected to rapid and transient
fluid flow and behaving as viscous liquid when exposed to slow fluid flow of a longer
duration. Again, take the vocal fold as an example, HA is a major modulator of the tissue
viscosity, providing shock absorbing properties to the tissue [38, 39]. Moreover, the shear-
thinning properties of HA create optimum conditions for phonation by decreasing the tissue
stiffness while vibrating [40]. The entangled HA network in the extracellular space also
effectively controls the solute/protein diffusion. Obviously, the viscoelastic properties of HA
and its hydration capacity depend on the molecular weight of HA. During rapid growth and
tissue remodeling, HA fulfills the requirements to fill the vacant space, to undergo
deformation, to maintain tissue hydration and to buffer the local environment. Such an HA-
rich environment can keep cells partially localized or provide cells with a substrate on which
to migrate [41, 42].
HA synthesis and degradation is tightly regulated during embryonic development and
homoeostatic processes. The half-life of HA varies from less than a day in rapidly turning
over skin and serum to typically 2–3 weeks in cartilage. HA is removed from the ECM as a
consequence of local catabolism and/or drainage into the lymphatic system for catabolism in
regional lymph nodes. HA can be catabolized by a number of enzymes in the hyaluronidase
(HAase) family. Hyal1 and Hyal2 are the two most common and ubiquitously important
HAases. Both enzymes are found in almost all somatic tissues [43]. Hyal1 is present in two
isoforms, the first being a 57 kDa glycosylated protein and the second being a 45 kDa form
with approximately 100 amino acids deleted [44, 45]. Both in vivo and in vitro studies have
demonstrated that the larger isoform likely is secreted by the cell while the smaller isoform
is retained in acidic intracellular vesicles [46]. Hyal2 often is found in a
glycosylphosphatidylinositol (GPI)-anchored form, tethered to the extracellular side of the
plasma membrane [47, 48]. Hyal3 and PH-20 are more specialized HAases. Hyal3 has been
poorly studied, but has been shown to be an intracellular HAase expressed in specific tissues
[49]. PH-20 is classically known as the sperm HAase involved in fertilization, and is rare in
other human tissues. Like Hyal1, PH-20 has two forms, a larger, GPI-linked isoform that is
anchored to the plasma membrane and a smaller, soluble isoform caused by removal of 56
amino acids at the C-terminus [50].
The HAases have differential activities in the HA fragment sizes they generate and the pH at
which they show optimal activity. Hyal1 is only active at very low pH values from 3.5 – 3.8.
The enzyme cleaves large or small molecular weight HA into tetramers [51]. Hyal2 shows
optimal activity at pH 6.0 – 7.0, but is active over a large pH range. This enzyme cleaves
high molecular weight HA into intermediate size fragments of approximately 20 kDa [52].
PH-20 is active over a relatively wide pH range between 3.0 and 9.0. PH-20 degrades high
molecular weight HA into small fragments although some intermediate size fragments also
are present [51].
Hyal1 and Hyal2 work in concert to degrade HA in somatic cells (Figure 1C). GPI-anchored
Hyal2 binds HA extracellularly, likely in concert with HA receptors, then internalizes HA
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and performs preliminary cleavages on the full length HA polymer in acidic endocytic
vesicles [53]. From there, Hyal1 can further process HA oligomers in these vesicles with the
help of p-exoglycosidases, which can cleave sugar groups off each terminus [46]. Gene
knockout studies have supported this theory, demonstrating that the action of Hyal1 can be
largely compensated for by p-exoglycosidases [54], whereas Hyal2 deficient mice are either
embryonic lethal or have severe defects [55].
In addition to the enzymatic degradation, HA can be fragmented by reactive oxygen species
(ROS) generated by many types of cells under stressed conditions [56] and HA degradation
by superoxide and peroxynitrite in various injury models has been studied [57–62].
Interestingly, HA and its degraded fragments have extraordinarily wide-ranging and often
opposing biological functions, owing to the activation of different signal transduction
pathways. This variation might be a mechanism by which nature diversifies the functions of
a simple polysaccharide [63]. High molecular weight HA species with >1000–5000
saccharide repeats are space-filling, anti-angiogenic, and immunosuppressive; they impede
differentiation, possibly by suppressing cell–cell interactions, or ligand access to cell surface
receptors. HA chains up to 20 MDa are involved in ovulation, embryogenesis, wound repair
and tissue regeneration [63]. Studies have shown that, in response to HA of 40–400 kDa, the
NF-kB-mediated gene expression is activated by HA binding with HA receptor for
endocytosis (HARE) [64]. Malignant cells produce HA polysaccharides in order to co-opt
normal cellular functions. On the other hand, the ability of the naked mole rat to synthesize
high molecular mass HA (5 times larger than human HA) is correlated to the cancer
resistance and longevity of this species [65]. Contrarily, HA fragments of lower molecular
weight are inflammatory (1000 repeats), immunostimulatory and pro-angiogenic (8–32
saccharide repeats), and they competitively bind HA receptors on cell surfaces. Under
certain conditions, low-molecular-weight HA species (20–200 kDa) function as endogenous
“danger signals”, while even smaller fragments can ameliorate these effects [66].
3. HA-protein interactions
While HA alone has distinct biophysical and biomechanical properties, the biological
functions of HA manifest through its interactions with a large number of HA-binding
proteins (HABPs, or hyaladherins) that exhibit significant differences in their tissue
expression, cellular localization, specificity, affinity and regulation [67, 68]. A number of
HABPs bind HA through binding motifs with the sequence B(X7)B where B is a basic
residue, arginine or lysine, and the X’s contain at least one basic amino acid but can be any
other non-acidic amino acids [69]. Additionally, a second HA binding motif, known as the
link module, consists of a span of about 100 amino acids which binds HA when oriented in
the correct tertiary structure [70]. A third possible binding motif is an arginine-arginine (R-
R) sequence that has been shown biochemically to bind HA, but has not been thoroughly
studied in full length proteins [71].
HABPs can be classified based on the binding motif that is used to bind HA. Members of
the family that use the link module in binding HA include cluster of differentiation 44
(CD44), hyaluronectin, aggrecan, versican, lymphatic vessel endothelial receptor 1
(LYVE-1), and tumor necrosis factor-a stimulated gene 6 (TSG-6). The family of proteins
that use the B(X7)B motif includes receptor for hyaluronan mediated motility (RHAMM),
cdc37, P-32, and sialoprotein associated with cones and rods (SPACR). Given that HABPs
generally interact with a minimal of 6–10 sugar repeats of HA [63], a single chain of high
molecular weight HA can theoretically accommodate in the order of 1000 protein molecules
[72]. In general, cellular signaling responses induced by HA/HABP interactions are strongly
dependent on HA molecular weight and the cell phenotype [73].
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CD44 is a multi-domain, ubiquitous HA receptor protein that spans the plasma membrane of
the cell. It contains highly conserved membrane spanning, cytoplasmic, and HA binding
domains while the membrane proximal region is poorly conserved among mammalian
species. Ten alternatively spliced exons reside in the poorly conserved, extracellular region.
The standard version of CD44 (CD44s) has all ten of these variant exons removed.
Estimated mathematically, over 800 variant forms of CD44 (CD44v) could be created with
the ten alternatively spliced exons, although not all of these combinations are expressed.
Over 20 unique forms of CD44v have been identified to date [74]. The core protein of
CD44s is only 37 kDa in size, but is increased to between 80 to 90 kDa through the addition
of multiple oligosaccharide and GAG additions. CD44v can contain additional modifications
because many of the variant exons contain sites for additional oligosaccharide and GAG
additions [75]. These variant exons therefore affect the affinity of CD44 for HA binding
based on the concept that the N-linked glycosylation pattern dictates the activation state of
CD44. Specifically, a high degree of N-linked glycosylation activates CD44 to bind HA,
while a low degree inactivates CD44 so that it binds HA poorly or not at all [75]. The
activation patterns of CD44 also are affected by the type of cell, phosphorylation state of the
cytoplasmic tail, and clustering in the membrane [76]. CD44/HA binding is involved in
diverse functions including attachment, organization, and turnover of the ECM at the cell
surface, as well as the mediation of lymphocyte migration during inflammation.
Another HABP, RHAMM, also known as CD168, was originally discovered as a soluble
protein that altered migratory cell behavior [77]. In contrast to CD44 and other cell-surface
receptors that contain the classical membrane spanning domain and signal sequence for
secretion from the endoplasmic reticulum (ER)/Golgi complex, RHAMM does not contain a
membrane spanning domain nor does the mRNA transcript contain a signal sequence.
RHAMM normally is localized inside the cell and is only released by certain, poorly defined
stimuli. The transport of RHAMM to the extracellular space is still unclear but may involve
transport channels proteins, flippase activity, or exocytosis [78]. Intracellularly, RHAMM
associates with microtubules and, working with breast cancer-2 susceptibility protein
(BRCA2) and BRCA1-associated RING domain protein 1 (BARD1), plays a role in the
regulation of mitosis [79]. Extracellularly, RHAMM associates with CD44, and upon
binding to HA, activates intracellular signaling pathways [80]. Variants of RHAMM caused
by alternative splicing have been observed, but not thoroughly studied. Preliminary reports
have suggested that alternatively spliced forms of RHAMM may be upregulated in some
tumor types, promoting tumor progression [81].
Expressed on the endothelial cells of the lymphatic sinus and in reticular cells in the lymph
nodes, LYVE-1 binds HA via the link module to mediate the transport of HA from tissue
ECM to lymph for cell uptake and degradation [82]. Based on the amino acid sequence,
LYVE-1 is predicted to be a type I transmembrane glycoprotein, with a single copy of
CD44-like link module located at the N-terminus of the extracellular domain that binds both
soluble and immobilized HA [83, 84]. LYVE-1 has been widely used as a lymphatic vessel
specific marker and offers a prognostic parameter for head and neck squamous cell
carcinomas. Although the HA-binding capacity of LYVE-1 is highly regulated, HA
homeostasis in LYVE-deficient mice is not perturbed [85]. Further investigations are
necessary to identify the role of LYVE-1 in normal lymphatic development and function, as
well as its involvement in lymphatic HA metabolism or HA-mediated cell migration.
HA can be organized into supramolecular assemblies via its association with multiple
binding proteins [72, 86]. In the ECM of connective tissues, HA binds certain proteoglycans,
such as aggrecan (Figure 3), versican, and brevican, to form large complexes that provide
the structural integrity and mechanical functions to the tissues [87–89]. The protein product
of TSG-6, secreted in response to inflammatory stimuli, also binds HA via a single link
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module. Binding of TSG-6 with HA results in the formation of fibrils or “cables” (Figure
4A) that are pro-adhesive to lymphocytic cell lines. Adhesion of leukocytes to the HA
complexes prevents the direct contact of inflammation-promoting receptors to the
underlying tissues, thereby maintaining leukocytes in a non-activated state. In response to
ER stress or when exposed to high concentrations of glucose, a variety of cells produce HA
cables [90]. TSG-6 catalyzes the covalent transfer of heavy chains (HCs) from inter-alpha-
trypsin inhibitor (IocI) and pre-α-inhibitor (PαI) to HA, and HC-HC crosslinks results in
stabilized HA cables [91–93]. Certain HA cables, for example, those synthesized by airway
smooth muscle cells, can form without TSG-6 and are independent of HC attachment [94].
With an overall length greater than 200 µm long, these cables are capable of supporting the
binding of a large number of leukocytes. Versican is found to associate with the cables,
extending and hydrating these structures, as well as providing a means of sequestering
proinflammatory chemokines through interactions with its chondroitin sulfate and dermatan
sulfate chains [95].
The pericellular coat (Figure 4B–C), an HA-rich, 5–10 µm thick gel-like layer surrounding
many types of cells, is also organized and stabilized by HABPs. The HA coat is organized
by aggregating proteoglycan and cell surface HA receptors (CD44) and is crosslinked by
various proteins such as tenascin, TSG-6, IαI, pentraxin (PTX) and thrombospondin 1
(TSP-1). The pericellular coat plays complex roles in cell adhesion/de-adhesion and cell
shape changes associated with proliferation and locomotion, thereby contributing to the
regulation of inflammation, morphogenesis, tissue regeneration and healing. The elastomeric
pericellular matrix has also been implicated in cellular mechanotransduction [27, 96]. The
HA coat, formed between the cumulus cells surrounding the oocyte during ovulation, is
responsible for the integrity of the cumulus-oocyte complex, providing protection and
facilitating the transport of the oocyte into the oviduct for fertilization. Sperm-associated
hyaluronidases allow penetration of this matrix at fertilization [5, 97].
4. HA in morphogenesis and wound healing
Mounting evidence points to the involvement of HA in morphogenesis. HA-rich matrix can
either facilitate cell migration by creating hydrated and non-adhesive milieu or inhibit cell
migration via the increased binding of proteoglycans to pericellular HA [98]. HA exerts a
profound effect on the “stemness” of hematopoietic stem cells (HSCs), human embryonic
stem cells (hESCs) and mesenchymal stem cells (MSCs). All three types of stem cells reside
in specific HA-rich microenvironments that maintain cells in a quiescent state with low
levels of proliferation. The maintenance and differentiation of stem cells are also intimately
mediated by HA/HABP interactions. Specifically, HA/CD44 and HA/RHAMM interactions
are essential for the trafficking of HSCs and their homing into the bone marrow where they
are maintained in an undifferentiated state [99]. In embryonic tissues, RHAMM plays an
important role in the maintenance of hESC pluripotency, viability, and cell cycle. During
stem cell differentiation, RHAMM expression is significantly downregulated, at the same
time, HAS2 expression is markedly enhanced, resulting in a 13–24-fold increase in HA
production [100]. MSCs are resident stem cells in adult tissues and CD44 long has been
used as a marker for MSCs [101]. In response to platelet-derived growth factor (PDGF)
stimulation, MSCs express high levels of CD44 standard isoform, which facilitates cell
migration through interaction with extracellular HA. Such a migratory mechanism could be
critical for the recruitment of MSC into wound sites for the preparation of tissue
regeneration [102]. From a biomedical engineering perspective, delivering stem cells in HA
matrices not only improves cell survival, but also allows the cells to be released to
contribute to tissue regeneration owing to the susceptibility of the HA matrices to enzymatic
degradation.
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HA, alone or through its interaction with its binding partners, has been shown to be crucial
for the morphogenesis of many tissues/organs. For example, HA produced by endocardial
cells during embryonic development contributes to the formation of endocardial cushions
and facilitates the endothelial-to-mesenchymal transformation in the development of cardiac
valves. The maintenance of HA homeostasis, thereby the size of the endocardial cushions, is
achieved through balanced activity of positive and negative regulators of HAS2 [103]. HA is
also widely distributed throughout the developing central nervous system (CNS), playing a
role in regulating neural crest cell migration from the dorsal neural tube. Specifically, HA
promotes the separation of neural crest cells from the dorsal neural tube. In addition to
regulating neuronal function and cell migration, HA may influence progenitor cell
differentiation and maturation. It has been reported that the presence of HA either in vivo or
in vitro blocked the maturation of oligodendrocyte progenitor cells into myelin-forming
oligodendrocytes, suggesting that HA blocks remyelination by maintaining progenitor cells
in an undifferentiated or immature state. Neural stem cells (NSCs) may be influenced
similarly by exposure to HA in stem cell niches and in injury microenvironments, where
they may synthesize their own pericellular HA [68]. Delivery of NSCs in a HA-containing
hydrogel into stroke cavity promotes NSC maturation and proliferation [104]. Being a major
component of the ECM of the developing limb bud, HA is involved in various aspects of
limb morphogenesis. Importantly, down-regulation of HA is necessary for the cell
positioning, cell-cell interaction and cartilage differentiation during condensation. The
overexpression of HAS2 in the mesoderm of the chick limb bud in vivo results in the
formation of shortened and severely malformed limbs that lack one or more skeletal
elements [105–107].
Tissue injury and repair process is characterized by the turnover the matrix components, and
HA plays important and multifaceted roles in this dynamic process [108]. Interactions
between HA and its signaling receptors initiate inflammatory responses, maintain structural
cell integrity, and promote recovery from tissue injury. Studies have shown that RHAMM is
critical for the recruitment of macrophage to areas of tissue injury [109], whereas CD44 is
critical for abrogation of inflammation [110]. Moreover, Toll-Like receptors cooperate with
HA receptors, particularly with CD44, to activate the innate immune system [111–115]. The
ability of HA to facilitate tissue repair and wound healing depends on its molecular weight
and tissue location, as well as the specific cell population HA interacts with. The HA rich
matrix, both in the early inflammatory phase of wound repair and in the granulation tissue,
facilitates cell migration into the provisional wound matrix by providing an open hydrated
matrix and through direct interaction with cells via HABPs [68]. Fibroblasts recruited to the
wound bed produce proinflammatory cytokines that in turn, stimulate endothelial cells to
produce HA, further promoting the adhesion of cytokine-activated lymphocytes through the
HA-binding variant of CD44 [116]. HA also facilitates the cell detachment from the matrix
and cell mitosis, thereby fostering cell proliferation [117]. Through its interaction with
HABPs and aggregating proteoglycan, HA contributes to the organization of the granulation
tissue matrix. Experimental results suggest that CD44 may contribute to the organization
and/or stability of developing endothelial tubular networks [118]. Finally, the physiological
role of HA and its oligosaccharide are central to angiogenesis, an important step in wound
healing [108]. As mentioned above and consistent with this idea, high molecular weight HA
has been shown to inhibit angiogenesis, while the low molecular weight counterparts
promote angiogenesis and enhance the production of collagens by endothelial cells [119].
Noteworthy, intact, high molecular weight HA, not the fragmented HA, promotes the
induction of regulatory T-cells [120]. Thus, the induction signals can be recapitulated using
HA-containing synthetic matrices.
In the later stage of wound healing, HA may function as a moderator of inflammation by
protecting against free radical damage to cells [121]. The TSG-6/IaI complex, through its
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interaction with HA both on the cell surface and in the ECM, may serve as a potent negative
feedback loop to moderate inflammation and to stabilize the granulation tissue as healing
progresses. The final stages of wound healing include re-epithelialization and remodeling. In
healing wounds, HA is expressed in the wound margin, in the connective tissue matrix, and
collocating with CD44 expression in migrating keratinocytes [122]. Interestingly, fetal
wound healing is characterized by a lack of fibrous scarring. HA in fetal wounds remains
high for longer periods than in adult wounds, probably reducing the deposition of
disorganized collagen matrix. The persistent HA-rich environment can affect cell-cell and
cell-matrix interactions, ultimately contributing to scarless wound healing as can occur in
the HA-rich young organism [108]. In adult tissues, studies show that blocking signaling of
HA fragments by using a RHAMM-mimetic peptide results in skin wound healing with
reduced fibrosis [123].
5. HA in cancer
Tumor progression and metastasis are accompanied by the alteration of organ
microenvironment. HA is enriched in many types of tumors and has been implicated in the
progression and metastasis of carcinomas [27]. Enrichment of HA in tumors can be
attributed to increased production by tumor cells themselves or by tumor associated stromal
cells through tumor-stroma crosstalk [124]. For example, normally absent in healthy
epithelial tissues, HA is upregulated when the epithelial cells undergo malignant
transformation [98]. The involvement of HA in the growth and spreading of cancers of
epithelial origin is complex and multifaceted. During tumorigenesis, epithelial cells can
undergo epithelial-to-mesenchymal transition and detach themselves from the epithelial
compartment for invasion, accompanied by enhanced HA synthesis. HA, in turn, supports
cell proliferation, prevents apoptosis, maintains intercellular space to facilitate nutrient
diffusion, and enhances cell locomotion that stimulates invasion. In addition, cancer cells
disguise themselves with a coat of HA from the cytotoxic effects of T-lymphocytes. HA
cables, on the other hand, bind tissue macrophages and modulate their activity to favor
tumor growth [98].
The upregulation of HAS expression results in the accumulation of HA in tumor tissues and
consequently, the creation of a pro-metastatic microenvironment [125]. Using a clone of
breast cancer cell line MDA-MB-231 that forms bone metastases in an in vivo-like basement
membrane model, researchers discovered that the increased expression of HAS2 in
metastatic cells resulted in a 7-fold higher HA-synthesizing capacity compared with MDA-
MB-231 cells [126]. Further, knockdown of HAS2 completely suppressed the invasive
capability of these cells by the induction of tissue metalloproteinase inhibitor 1 (TIMP-1)
and dephosphorylation of focal adhesion kinase (FAK). HAS2 knockdown-mediated
inhibition of basement membrane remodeling was rescued by HAS2 overexpression,
transfection with TIMP-1 siRNA, or addition of TIMP-1-blocking antibodies. Moreover,
knockdown of HAS2 suppressed the EGF-mediated induction of the FAK/PI3K/Akt
signaling pathway [126]. HAS2 has also been shown to be critical for the interaction of
cancer stem cells (CSCs) with tumor-associated macrophages (TAM), leading to enhanced
secretion of platelet-derived growth factor-BB from TAMs. This secretion could then
activate stromal cells and enhance CSC self-renewal. Loss of HAS2 in CSCs or inhibition of
HAS activity drastically reduced the incidence and growth of metastatic lesions in vitro or in
vivo, respectively. [127]
It is noteworthy that, while a moderate increase in HA production correlates with tumor
growth and metastasis, a large excess of HA can suppress tumor growth [128]. Because HA
accumulation is the result of a balance between the activities of HAS isozymes and HAases,
the presence of HAases may promote HA turnover in the cancer cells and overcome the
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tumor suppression by excess amounts of HA. By degrading the HA-rich matrix surrounding
the tumor, HAases help the cancer cells escape from the primary tumor mass and play a
major role in intravasation by allowing degradation of the basement membrane of the lymph
or blood vessel. HAases play roles in the establishment of a metastatic lesion by helping
with extravasation and clearing the ECM of the secondary site [129]. Finally, HAases
produce HA fragments to stimulate endothelial cell proliferation and budding of new
capillaries that promote angiogenesis to allow tumor expansion [130]. Interestingly, hypoxia
also increases production of HA and activity of HAases [131].
Each of the HAases discussed above can play a role in cancer progression, although the
roles they play and the cancers they contribute to may differ. Earlier in vitro cell culture
experiments suggested that Hyal1 expression prevented tumor growth from the results of
cells cultured in vitro [132]. Furthermore, when directly injected, Hyal-1 was found to
inhibit tumor formation in vivo [133]. Subsequently, it was discovered that context matters
in the case of the role of Hyal1 in cancer progression. Hyal1 plays a role in metastasis
mainly via interactions with the ECM, and a lack of this tumor microenvironment would
likely complicate the data in an in vitro setting. Additionally, Hyal1 functions predominantly
in an intracellular fashion, explaining why direct injection of this enzyme may produce
conflicting results. Clinically, there is considerable interest in using Hyal1 levels in blood or
urine to predict a patient’s prognosis. Studies among bladder cancer patients show that
Hyal1 levels correlated positively with poor prognosis, muscle invasion, and recurrence
[134, 135]. In prostate cancer (PCa) patients, high Hyal1 levels correlate with progression
84% of the time [136]. Hyal1 is the predominant HAase responsible for lung cancers as well
[137]. Laboratory studies have shown similar results. PCa cells that over-express Hyal1
form significantly more metastases than do controls that express lower levels of the enzyme
[138].
Some research has been performed to examine the role of Hyal2 in cancer metastasis,
however the accumulated data indicates that Hyal2 likely plays a role. A clinical study found
that endometrial cancer cells express more Hyal2 than Hyal1 pointing to its importance in
that type of cancer [139]. Additionally, a cell based study found that highly invasive breast
cancer cell lines express more Hyal2 than poorly invasive lines [140]. When Hyal2 was
over-expressed in astrocytoma cells, these cells formed more aggressive, invasive tumors in
the cranium compared to control. Interestingly, the same result was not found when the cells
were injected subcutaneously, indicating that the microenvironment matters for the role of
Hyal2 in cancer progression [141].
The role of Hyal3 in cancer progression is poorly studied and the few studies that have
investigated this HAase report contradictory results. A study of breast cancer cell lines
demonstrated that poorly invasive lines express more Hyal3 than do highly invasive lines
[140]. On the other hand, a study of endometrial cancer found that Hyal3 was expressed at
levels 1000 times higher than Hyal1 and 33 times higher than Hyal2 suggesting that Hyal3 is
the main HAase necessary for endometrial cancer progression [139]. The finding that PH-20
is normally expressed only in the testes is of interest to the medical community because it
could provide a good prognostic indicator of the existence of cancer and the likelihood to
metastasize. Two studies on laryngeal cancer have shown that PH-20 expression increased
in late stage tumors, or those likely to metastasize [142, 143]. A similar correlation was
shown for breast cancer [144, 145]. African-American women with breast cancer were
shown to have a higher expression of PH-20 compared to Caucasian women, an interesting
observation considering that African-Americans have a higher likelihood of breast cancer
metastasis [146]. Collectively, the existing data demonstrates that PH-20 plays a strong role
in cancer metastasis, at least for some cancers.
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HA also interacts with its receptors to modulate cell behaviors during tumor progression and
metastasis. Among the HA receptors, CD44 has been best studied. Numerous clinical studies
have shown that increased expression of CD44 correlates with increased metastasis of a
variety of different tumors [147]. In addition to a wealth of clinical data, the pathways by
which CD44 affects cancer metastasis also have been largely determined. Collectively,
CD44 affects adhesion of cancer cells, rearranges of the cytoskeleton through activation of
Rho GTPases, and increases the activity of ECM degrading enzymes.
When a cell remains epithelial in nature by expressing E-cadherin, CD44/HA binding is low,
preventing the activation of metastatic signaling pathways [148]. When a cell becomes
cancerous, E-cadherin is down-regulated, leading to higher CD44/HA binding. After binding
with HA, CD44 signals for the activation of a number of ECM degrading proteins, which
allow cancer cells to detach from the primary tumor mass and migrate. CD44 increases
matrix metalloproteinase-9 (MMP-9) localization to the plasma membrane and optimizes
Hyal-2 activity by adjusting extracellular pH through activation of a Na+/H+ exchanger
[149, 150]. CD44 itself can be cleaved by MMPs, again helping cancer cells release
themselves from the tumor mass [151, 152]. An intracellular cleavage product of CD44
produced by y-secretase can participate in transduction leading to increased migration [153].
CD44 activates a number of Rho GTPases that remodel the actin cytoskeleton to allow for
migration to occur. Binding of CD44 to HA controls activation of RhoA, Rac1, and Cdc42
GTPases, and subsequently the downstream targets of these GTPases [154–156]. Along with
remodeling the actin cytoskeleton, CD44 also activates FAK, which allows for focal
adhesion formation and turnover, another key step in the process of cell motility [157].
Another molecule that promotes invasion that CD44 activates is Snail2, through the NFkB
pathway [158]. Other downstream targets of CD44 likely exist, but have not yet been
discovered. While it is important that CD44 molecules be cleaved for the cancer cells to
release from the primary tumor mass, interactions between the receptor and HA and other
ECM molecules during the metastatic process also are important. Several isoforms of
CD44v are necessary for cell motility by binding with HA and other ECM components
[159–161]. Additionally, CD44 is indispensable during the processes of intravasation and
extravasation because it regulates binding of the cancer cell to endothelial cells [162].
While RHAMM has been less well studied than CD44 in the progression of cancer
metastasis, the research that has been produced shows that it is likely just as important in
this process and probably plays a larger role in cell motility than does CD44. Increased
RHAMM expression is correlated with metastases in colrectal cancer, among others [163,
164]. Mechanistically, RHAMM promotes cell motility through a number of different
pathways. As is seen with CD44, RHAMM can promote focal adhesion turnover by
controlling FAK phosphorylation and by cooperating with the α4β1 and α5β1 integrins [165,
166]. RHAMM also activates a number of downstream kinases including Erk 1/2 through
the mitogen activated protein kinase (MAPK) pathway, pp60 (c-src), and the downstream
targets of Rho kinase (ROK) [167–169]. Finally, once a metastatic lesion has been
established, RHAMM can cooperate with CD44 to promote angiogenesis by promoting
migration of neighboring endothelial cells towards the tumor [170].
The understanding of HA in cancer biology has led to successful clinical usage of HA for
cancer treatment. For example, to improve the treatment of tumors, Halozyme Therapeutics
[171] uses recombinant human of HAase (PH-20) to temporarily degrades HA, thereby
facilitating the penetration and diffusion of other drugs and fluids that are injected under the
skin. The use of HA by Tracey Brown and her team as drug carriers[172] for the treatment
of cancer has been successfully demonstrated in clinical trials [173].
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6. HA in biomedical applications
The ubiquitous presence of HA in various tissues, combined with its inherent
biocompatibility and biodegradability, has motivated researchers to explore the utility of
HA-based materials for tissue growth, repair and regeneration [18, 174]. In this special
issue, Segura and colleagues have summarized strategies for preparing HA-based hydrogel
scaffolds with desired cell-instructive features for tissue engineering and regenerative
medicine applications. Many HA-derived medical products have been developed and tested
and the readers are referred to recent reviews [17, 175] for in-depth analyses. In this article,
we highlight our own experiences in the application of HA-based hydrogels for the repair
and regeneration of healthy functional tissues, such as vocal folds [176–179], cartilage [180,
181] and salivary glands [182, 183], as well as the creation of pathological tissue models,
such as tumor spheroids [184–186].
Using chemically modified HA derivatives as modular building blocks, we have engineered
HA hydrogel particles (HGPs) and complex networks with defined biological functions and
robust mechanical properties[18]. For example, nanoporous, micron-sized HA HGPs were
synthesized using different inverse emulsion systems and crosslinking chemistries. The
resultant particles either contained residual functional groups or were rendered reactive by
subsequent chemical modifications. HA-based doubly crosslinked networks (DXNs) were
synthesized via covalent crosslinking of HA HGPs with soluble HA macromers carrying
mutually reactive functional groups. These hybrid matrices are hierarchical in nature,
consisting of densely crosslinked HGPs integrated in a loosely connected secondary matrix
[178]. Their mechanical properties and degradation kinetics can be readily tuned by varying
the particle size, functional group density, and intra- and interparticle crosslinking. Using a
custom-designed torsional wave apparatus [187], we demonstrated that the viscoelastic
properties of HA DXNs can be matched to that of the vocal fold tissue samples [188] at
frequencies close to human phonation. Thus, these materials are attractive injectables for the
elimination of vocal fold scarring [178, 189]. Separately, HA hydrogels containing self-
assembled collagen fibrils provide instructive matrices for the 3D culture of primary vocal
fold fibroblasts (PVFFs). PVFFs are found to attach and spread in the matrix and proliferate
readily. TWA analysis suggests that PVFFs residing in gels alter the matrix organization,
chemical compositions and viscoelasticity through cell-mediated remodeling processes
[179].
HA-based complex networks also have been evaluated for the repair of the cartilage and the
regeneration of cartilage-bone interface. In this context, the nanoporous HA HGPs are ideal
growth factor depots for chondrogenic cytokines and growth factors. To improve the
biological functions of HA HGPs, perlecan/HSPG2 domain I (PlnDI), a basement membrane
proteoglycan that has strong affinity for various heparin binding g rowth factors (HBGFs),
was successfully conjugated to the particles through the core protein via a flexible
poly(ethylene glycol) (PEG) linker. The immobilized PlnDI maintains its ability to bind
bone morphogenetic proteins (BMP-2) and modulates its release [190]. The chondrogenic
potential of the hydrogel particles and the stimulatory effects of the injectable formulation
were confirmed in vitro using micromass culture of multipotent MSCs and in vivo in a
reversible animal model of osteoarthritis (OA). Finally, celladhesive HA DXNs were
fabricated by encapsulating gelatin, or collagen-like peptide-decorated HA HGPs in a
secondary HA matrix [191]. Human MSCs were shown to adhere to the composite matrix
through the focal adhesion sites clustered on particle surfaces. The celladhesive composite
matrices supported hMSC proliferation and migration into the gels. Human MSCs were
undifferentiated during the early time points of culture. However, they differentiated into
osteoblast phenotype after 28 days of culture [192].
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Cartilage is routinely exposed to regular compression during locomotion. Integrating
mechano-responsive elements in HA hydrogels is a novel strategy to harvest the
compressive forces in the tissue to effectively direct cellular behaviors. To achieve this goal,
self-assembled block copolymer micelles (BCMs) containing a hydrophobic, rubbery core
and a hydrophilic shell with chemically addressable groups were utilized as the dynamic
building blocks and microscopic crosslinkers [193, 194]. Covalent integration of
dexamethasone (DEX)-loaded BCMs in HA gels significantly reduced the initial burst
release and provided sustained DEX release over a prolonged period. Importantly, DEX
release from BCM-HA gels was accelerated by intermittently-applied external compression
in a strain-dependent manner. Culturing macrophages in the presence of DEX-releasing
BCM-HA gels significantly reduced cellular production of inflammatory cytokines, possibly
through the synergistic actions of HA and the released DEX [195]. Incorporating mechano-
responsive modules in synthetic matrices offers a novel strategy to harvest mechanical stress
present in the healing wounds to initiate tissue repair.
Although not present at high levels in healthy salivary glands, the biocompatibility and the
bioactivity of HA motivated us to investigate HA-based gels for the creation of artificial
salivary glands for the treatment of xerostomia, or dry mouth. Parotid cells encapsulated in
3D HA hydrogels self-assembled into acini-like structures and expressed functional
neurotransmitter receptors [183]. Structures in 3D hydrogels merged to form organized 50
µm spheroids that could be maintained in culture for over 100 days and merged to form
structures over 500 µm in size. Treatment of acini-like structures with the β-adrenergic
agonists increased granule production and α-amylase staining in treated structures,
demonstrating regain of protein secretion. Upon treatment with the M3 muscarinic agonist
acetylcholine, acini-like structures activated the fluid production pathway by increasing
intracellular calcium levels. Encapsulated cells in 3D retained their spheroid structure and
structural integrity, along with the salivary biomarkers and maintained viability for over
three weeks in vivo. Thus, the HA hydrogels are capable of maintaining functional 3D
salivary spheroid structures for long periods in vitro that retain both fluid and protein
secreting functions and are suitable for tissue restoration [183].
The utility of HA-based matrices for the engineering of healthy replacement tissues has been
expanded to the construction of pathological tissue models. We have developed a
biologically relevant hydrogel culture system [184] that recaptures the essential feature of
prostate cancer (PCa) and its associated stroma. Cell-laden hydrogels were prepared by
mixing HA derivatives carrying complementary reactive groups. The resultant viscoelastic
hydrogels are biodegradable and can interact with prostate cancer cells through its receptors,
activating specific signaling pathways [185]. Prostate cancer (PCa) cells entrapped in HA
matrices formed distinct multicellular aggregates which grew and merged, reminiscent of
real tumors, whereas cells cultured on 2D monolayer adopted an atypical spread-out
morphology.
The engineered tumor model was used successfully to test the efficacy of anti-cancer drugs
including camptothecin, docetaxel, and rapamycin, alone and in combination, including
specificity, dose and time responses. Responses of cells to anti-neoplastics differed between
the 3D HA hydrogel and 2D monolayer systems [184]. The engineered tumor models also
have the potential to provide predictable results for the in vivo assessment of nanomedicine.
Specifically, doxorubicin (Dox) loaded NPs with an average diameter of 54±1 nm were able
to diffuse into the hydrogel matrices, reach and penetrate into the tumoroids, be internalized
by LNCaP PCa cells through caveolae-mediated endocytosis and macropinocytosis
pathways, and finally release the drug intracellularly. A drug efficacy study revealed that
LNCaP PCa cells cultured in the 3D hydrogel were more resistant to Dox in both soluble
and NP-based form than were cells on 2D culture. In addition, the NP-based Dox
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formulation may bypass the drug efflux function of MRP1, thereby partially reversing drug
resistance in 3D cultures [196].
To simulate the tumor-stroma cross-talk, a bilayer construct was developed and
characterized. The top hydrogel layer contains heparin (HP)-decorated, HA-based HGPs
presenting heparin-binding epidermal growth factor-like growth factor (HB-EGF) in a
sustained manner. LNCaP cells were embedded within the bottom hydrogel layer and
received growth stimuli from the top. We demonstrated that tumoroids grown in bilayer HA
hydrogels reflect features reminiscent of native carcinoma, and exhibit promising angiogenic
potential through the upregulation of pro-angiogenic factors, both at the gene and the protein
levels. These structured 3D units provide a novel means to study cancer and stroma
invasiveness, cell-cell interactions and drug responses [186].
To study the individual functions of HA interacting proteins in PCa motility through
connective tissues, we have developed an invasion assay [185].based on the 3D HA
hydrogel that provides a flexible, quantifiable, and physiologically relevant alternative to
current methods. Metastatic PCa cells in these hydrogels develop fingerlike structures,
“invadopodia”, consistent with their invasive properties. The number of invadopodia, as
well as cluster size, shape, and convergence, can provide a quantifiable measure of invasive
potential. We found that culture in the HA hydrogel triggers invasive PCa cells to
differentially express and localize RHAMM/CD168 which, in the absence of CD44, appears
to contribute to PCa motility and invasion by interacting with the HA hydrogel components.
PCa cell invasion through the HA hydrogel also was found to depend on the activity of
HAases. While HAase activity was necessary for invadopodia and inter-connecting cluster
formation, activity alone was not sufficient for acquisition of invasiveness to occur. Our
results suggest that development of invasive behavior in 3D HA-based systems requires
development of additional cellular features, such as activation of motility associated
pathways that regulate formation of invadopodia.
7. Summary and Outlook
This review highlights fundamental functions of HA in the context of biological systems, as
a structural support and a signaling molecule. HA biosynthesis, tissue turnover and
homeostasis are coordinately maintained by three synthases and several hyaluronidases.
Traditionally known as an ECM molecule, HA is also found pericellular and intracellularly,
although its intracellular function is largely speculative. HA provides structural frameworks
for cells, functions as an extracellular molecule transmitting signals, and regulates a variety
of cell behaviors, including cell adhesion, motility, growth and differentiation. Binding of
HA to cell surface receptors activates various intracellular signaling cascades, such as c-Src,
Ras and mitogen-activated protein kinases (MAPK) [73] thereby regulating cell growth and
survival, cytoskeletal rearrangement, and active cell migration. The biological functions of
HA depend on the molecular size of HA, the HA binding proteins, its spatial and temporal
distribution in tissues, and the cellular background and tissue stages. Mounting evidence
confirms the involvement of HA in morphogenesis and would healing, and its role in cancer
progression and metastasis.
HA has been widely used by the biomedical community as a starting material for the
fabrication of hydrogel matrices, tissue engineering tools, drug delivery vehicles or drug
depot systems, and tissue filler or surgical devices [16, 197–199]. HA-based materials may
impart biological activity to cells, as evidenced by changes in cellular behavior, due to the
cells’ ability to interact with biomaterials based on HA compared to synthetic polymers,
such as poly(ethylene glycol) (PEG). For example, the ability of HA to maintain stem cells
in an undifferentiated state [200] and the involvement of HA-interacting proteins in tumor
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metastasis in HA gels [185] have been investigated. In drug delivery, the ability of HA to
bind cell surface receptors has been explored for drug targeting purposes [201]. Notably,
excessive chemical modification of HA alters its biological functions. Real-time imaging of
quantum dot (QD)-tagged HA derivatives revealed that HA-QD conjugates with 35 mol%
HA modification maintained the ability to bind HA receptors and were mainly accumulated
in the liver, while those with 68 mol% HA modification lost much of HA characteristics and
were evenly distributed throughout the body [202].
Considering the complexity of the biological functions of HA, particularly the connection
with pathologies including inflammation and cancer, care must be taken to ensure long term
safety of HA-based biomaterials. For example, the intra-articular injection of HA is widely
used for symptomatic knee osteoarthritis. In a systematic review of randomized trials in any
language that compared viscosupplementation with sham or nonintervention control in
adults with knee osteoarthritis, Reichenbach and coworkers found that in patients with knee
osteoarthritis, viscosupplementation is associated with a small and clinically irrelevant
benefit and an increased risk for serious adverse events. The authors cautioned that trial
quality was generally low and safety data were often not reported [203]. Concerns also exist
for using HA-based materials for cell delivery and other modalities in tissue engineering as
potentially causing/exacerbating cell migration and metastasis of the residual tumor cells
following chemotherapy [204]. In a landmark paper, Khaldoyanidi’s team [205] provided
experimental evidence that HA treatment does not stimulate but delays the growth of
residual cancer cells, which is an important parameter in establishing whether the use of HA
can enhance current chemotherapeutic strategies. As we continue to unravel the complex
functions of HA under different biological conditions and disease states, advanced
engineering strategies and surgical interventions will lead to the potential utility of HA-
based materials in translational applications.
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Figure 1.
Chemical structure of HA (A) and schematic illustration of HA biosynthesis (B) and
biodegradation (C). (A): HA is a linear polysaccharide with disaccharide repeats of D-
glucuronic acid and N-acetyl-D-glucosamine. (B): HA is synthesized by transmembrane
proteins HAS1, 2 and 3 and is extruded into the extracellular space as the polymerization
proceeds. (C): HA is internalized by binding to HA receptors and Hyal2 within caveolae.
Hyal2 cleaves HA into intermediate fragments that are transported to lysosomes. Lysosomal
Hyal1 cleaves HA into tetramers that are finally cleaved into HA monomers by
exoglycosidases. (A, B): Reproduced with permission [125], Copyright 2008, The Japanese
Biochemical Society (C): Reproduced with permission, Copyright 2013, Glycoforum.
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Figure 2.
Tapping Mode AFM images of HA deposited on freshly cleaved mica. HA with moderate
(A, B) or high molecular weight (C, D), produced in bacteria (A-C) or extracted from
rooster comb (D), was deposited from 10 µg/mL solution in H2O (A, B), 5 µg/mL solution
in 10 mM MgCl2 or 500 ug/mL solution in 0.15 M NaCl (D). Scale bar: 250 nm, Z range:
2.5–6 nm. Reproduced with permission [36], Copyright 2005, Elsevier.
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Figure 3.
HA organizes the cartilage ECM via noncovalent binding with aggrecan. (A): An electron
micrograph of an aggrecan/HA aggregate (from fetal bovine cartilage) shadowed with
platinum. (B): A drawing of the aggrecan/HA aggregate, showing the non-covalently
binding of aggrecan via the link proteins. Each aggregate consists of approximately 100
aggrecan monomers bound to HA. With a molecular weight >108, such a complex occupies
a volume equivalent to that of a bacterium. Reproduced with permission [206], Copyright
2002, Garland Science.
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Figure 4.
HA organized as monocyte-adhesive cables (A) or pericellular coat (B, C). (A): Monocyte-
adhesive HA cable, produced by treating human colon smooth muscle cells with poly I:C for
17 h. Green: HA; Red: CD44 and Blue: nuclei. Scale bar: 50 µm. Arrowheads point to areas
without any leukocytes. (B, C): HA coat around a MCF-7 cell, as revealed by confocal
imaging a probe made of aggrecan G1 domain and link protein tagged with Alexa Fluor
594® (red). Green staining represents green fluorescent protein tagged HAS3 (GFP-HAS3).
The HA coat was visualized particle exclusion using red blood cells (green). Scale bar: 10
µm. (A): Reproduced with permission [90], Copyright 2003, Elsevier. (B, C): Reduced with
permission [96], Copyright 2008, Elsevier.
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